Sevoflurane In Acute Myocardial Infarction

Sevoflurane Sedation During Primary Percutaneous Coronary Intervention.

Ischemic postconditioning can reduce myocardial injury following myocardial infarction.

A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflurane during primary percutaneous coronary intervention (PCI) will reduce infarct size.

Patients with first STEMI that will be treated by primary PCI, will be randomized to sedation with Sevoflurane during the procedure or to usual care.

Inclusion Criteria:

• First STEMI, presenting within 6 hours after the onset of chest pain
• Symptoms lasting > 30 minutes
• Persistent ST-segment elevation > 0.1 mV in 2 or more contiguous leads

Exclusion Criteria:

• Hypersensitivity to sevoflurane or other halogenated agents
• Malignant hyperthermia
• Cardiac arrest
• Cardiogenic shock
• Previous myocardial infarction or coronary bypass surgery
• Pre-infarction angina
• Heart failure (NYHA III/IV)
• Chronic inflammatory disease
• Severe renal impairment
• Hepatic dysfunction
• Use of Glyburide